Allergy/Asthma News

Although COVID-19 remained a popular topic among Healio Primary Care readers in 2021, other stories that discussed diabetes screening and physician suicide also generated significant attention.

As families and health care providers struggle to manage food allergies, 2021 saw significant advances in research and treatment. Here are our top 10 stories about developments and improvements benefitting these patients.

COVID-19 dominated 2021, as patients and providers balanced its treatment and prevention against their allergy and asthma needs.

Testing for Ana o 3, a 2S albumin of cashew nut, provided the most value in predicting clinical reactivity for cashew nut allergy compared with other methods, according to a study published in Annals of Allergy, Asthma & Immunology.

As of Dec. 1, the FDA had approved 46 novel drugs this year, one fewer than it had approved by the same date in 2020.

Most patients with severe cow’s milk allergy can be safely desensitized to substantial levels of baked milk through baked milk oral immunotherapy, according to a study published in The Journal of Allergy and Clinical Immunology.

The FDA issued an FDA Modernization Act health claim on Dec. 8 acknowledging the safety of the early introduction of peanuts among infants to reduce the risk for developing peanut allergy.

The FDA has approved tezepelumab for add-on maintenance treatment of adults and children aged 12 years and older with severe asthma.

Patients with asthma and stable public insurance or insurance instability, compared with stable private insurance, had increased odds of hospitalization, according to new data published in the Annals of the American Thoracic Society.

Food packaging often does not consistently label allergens such as sesame, putting many people at risk for adverse reactions, according to a study published in Annals of Allergy, Asthma & Immunology.